[1]周夜夜,邓胜明,章斌,等.18F-FDG PET/CT在儿童及青少年淋巴瘤诊治中的应用价值[J].国际放射医学核医学杂志,2018,(6):535-540.[doi:10.3760/cma.j.issn.1673-4114.2018.06.011]
　Zhou Yeye,Deng Shengming,Zhang Bin,et al.Value of 18F-FDG PET/CT for diagnosing and treating childhood and adolescent lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):535-540.[doi:10.3760/cma.j.issn.1673-4114.2018.06.011]
点击复制

18F-FDG PET/CT在儿童及青少年淋巴瘤诊治中的应用价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第6期
页码:
535-540
栏目:
综述
出版日期:
2018-12-31

文章信息/Info

Title:
Value of 18F-FDG PET/CT for diagnosing and treating childhood and adolescent lymphoma
作者:
周夜夜;  邓胜明;  章斌;  吴翼伟
215000, 苏州大学附属第一医院核医学科
Author(s):
Zhou Yeye;  Deng Shengming;  Zhang Bin;  Wu Yiwei
Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou 215000, China
关键词:
正电子发射断层显像计算机体层摄影术; 氟脱氧葡萄糖F18; 淋巴瘤; 儿童; 青少年
Keywords:
Positron emission tomography computed tomography; Fluorodeoxyglucose F18; Lymphoma; Child; Adolescent
DOI:
10.3760/cma.j.issn.1673-4114.2018.06.011
摘要:
儿童及青少年淋巴瘤占所有儿科恶性肿瘤的10%~15%，其多为高度侵袭性肿瘤，较成人更易侵犯结外组织。准确的分期以及早期疗效评价对儿童及青少年淋巴瘤患者具有重要价值。传统影像学方法（超声、CT、MRI及67Ga成像）在其诊治过程中存在一定的局限性，18F-FDG PET/CT是将PET的功能代谢显像与CT的解剖结构显像相融合的一种新型成像技术。笔者通过对18F-FDG PET/CT检查在儿童及青少年淋巴瘤中的分期、疗效评级、随访中的作用作一综述，发现18F-FDG PET/CT在淋巴结、脾脏监测方面具有更高的灵敏度，可通过一次显像发现更多的病灶，在分期方面的准确性优于传统影像学方法。同时，因其代谢改变早于解剖形态的改变，能更早期、准确地评估疗效，对残留病灶的性质进行判断。由于其较低的复发率，需权衡在随访过程中监测复发及辐射暴露之间的利弊关系。
Abstract:
Childhood and adolescent lymphomas account for 10%-15% of all pediatric cancers. Most cases of pediatric lymphoma involve highly aggressive tumors and extranodal sites. As such, accurate staging and early assessment of therapeutic response are of great value for lymphoma in children and adolescents. Conventional imaging modalities (e.g., ultrasound, CT, MRI, and 67Ga) present some limitations in their diagnosis and treatment. 18F-FDG PET/CT is a new imaging technique that combines the functional data of PET with the morphological information of CT. This article reviews the current role of 18F-FDG PET/CT in the staging, efficacy evaluation, and follow-up of childhood and adolescent lymphoma and finds that 18F-FDG PET/CT is more sensitive than other imaging techniques in monitoring lymph nodes and the spleen. By imaging more lesions, the accuracy of 18F-FDG PET/CT for staging is better than that achieved by traditional imaging methods. At the same time, because of its metabolic changes earlier than the anatomical changes, assessing treatment efficacy promptly and accurately, as well as determining the nature of residual lesions, may be possible. Because of its lower recurrence rate, the trade-offs between monitoring recurrence and radiation exposure during the follow-up period must be weighed.

参考文献/References:

[1] Ferrari C, Niccoli AA, Merenda N, et al. Pediatric Hodgkin Lymphoma:Predictive value of interim 18F-FDG PET/CT in therapy response assessment[J/OL]. Medicine (Baltimore), 2017, 96(5):e5973[2018-01-07]. https://www.ncbi.nlm.nih.gov/pubmed/28151888. DOI:10.1097/MD.0000000000005973.
[2] Agrawal K, Mittal BR, Bansal D, et al. Role of 18F FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin’s lymphoma[J]. Ann Nucl Med, 2013, 27(2):146-151. DOI:10.1007/s12149-012-0665-5.
[3] Chung EM, Pavio M. Pediatric Extranodal Lymphoma[J]. Radiol Clin North Am, 2016, 54(4):727-746. DOI:10.1016/j.rcl.2016.03. 004.
[4] Uslu L, Donig J, Link M, et al. Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies[J]. J Nucl Med, 2015, 56(2):274-286. DOI:10.2967/jnumed.114.146290.
[5] Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System[J]. J Clin Oncol, 2015, 33(18):2112-2118. DOI:10.1200/JCO.2014.59.7203.
[6] Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed:a study of 766 patients[J]. J Nucl Med, 2010, 51(1):25-30. DOI:10.2967/jnumed.109.067892.
[7] Bakhshi S, Radhakrishnan V, Sharma P, et al. Pediatric nonlymphoblastic non-Hodgkin lymphoma:baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation——a prospective study[J]. Radiology, 2012, 262(3):956-968. DOI:10.1148/ra diol.11110936.
[8] Kabickova E, Sumerauer D, Cumlivska E, et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease[J]. Eur J Nucl Med Mol Imaging, 2006, 33(9):1025-1031. DOI:10.1007/s00259-005-0019-9.
[9] Uslu L, Donig J, Link M, et al. Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies[J]. J Nucl Med, 2015, 56(2):274-286. DOI:10.2967/jnum ed.114.146290.
[10] Bakhshi S, Bhethanabhotla S, Kumar R, et al. Posttreatment PET/CT rather than interim PET/CT using Deauville Criteria predicts outcome in pediatric Hodgkin lymphoma:a prospective study comparing PET/CT with conventionalImaging[J]. J Nucl Med, 2017, 58(4):577-583. DOI:10.2967/jnu mmed.116.176511.
[11] Paulino AC, Margolin J, Dreyer Z, et al. Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma[J]. Pediatr Blood Cancer, 2012, 58(6):860-864. DOI:10.1002/pbc.23273.
[12] Zapata CP, Cuglievan B, Zapata CM, et al. PET/CT versus bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric malignancies[J/OL]. Pediatr Blood Cancer, 2018, 65(2)[2018-01-07]. https://www.ncbi.nlm.nih.gov/pubmed/28901637. DOI:10.1002/pbc.26814.
[13] Hassan A, Siddique M, Bashir H, et al. 18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin’s lymphoma:a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement[J]. Eur J Nucl Med Mol Imaging, 2017, 44(7):1198-1206. DOI:10.1007/s00259-017-3647-y.
[14] Kluge R, Kurch L, Montravers F, et al. FDG PET/CT in children and adolescents with lymphoma[J]. Pediatr Radiol, 2013, 43(4):406-417. DOI:10.1007/s00247-012-2559-z.
[15] Cheng G, Chen W, Chamroonrat W, et al. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients[J]. Eur J Nucl Med Mol Imaging, 2011, 38(8):1469-1476. DOI:10.1007/s00259-011-1815-z.
[16] Purz S, Mauz-Körholz C, Körholz D, et al.[18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma[J]. J Clin Oncol, 2011, 29(26):3523-3528. DOI:10.1200/JCO.2010.32.4996.
[17] Kluge R, Körholz D. Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma[J]. Klin Padiatr, 2011, 223(6):315-319. DOI:10.1055/s-0031-1287834.
[18] Cheng G, Servaes S, Zhuang H. Value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma[J]. Leuk Lymphoma, 2013, 54(4):737-742. DOI:10.3109/10428194.2012.727416.
[19] Kiratli PÖ, Tuncel M, Bar-Sever Z. Nuclear Medicine in Pediatric and Adolescent Tumors[J]. Semin Nucl Med, 2016, 6(4):308-323. DOI:10.1053/j.semnuclmed.2016.01.004.
[20] Seth R, Puri K, Singh P, et al. The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma[J]. Indian J Nucl Med, 2012, 27(3):141-144. DOI:10.4103/0972-3919.112717.
[21] Riad R, Omar W, Kotb M, et al. Role of PET/CT in malignant pediatric lymphoma[J]. Eur J Nucl Med Mol Imaging, 2010, 37(2):319-329. DOI:10.1007/s00259-009-1276-9.
[22] Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:Evolving Considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009, 50 Suppl 1:S122-150. DOI:10.2967/jnumed.108.057307.
[23] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol, 2007, 25(5):579-586. DOI:10.1200/JCO. 2006.09.2403.
[24] 覃春霞, 兰晓莉. PET/CT在恶性淋巴瘤疗效评估中的应用[J]. 临床内科杂志, 2015, 32(3):166-169. DOI:10.3969/j.issn.1001-9057.2015.03.006. Qin CX, Lan XL. Application of PET/CT in the evaluation of malignant lymphoma[J]. J Clin Intern Med, 2015, 32(3):166-169. DOI:10.3969/j.issn.1001-9057.2015.03.006.
[25] Bailly C, Eugène T, Couec ML, et al. Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy[J/OL]. Front Med (Lausanne), 2014, 1:54[2018-01-06]. https//www.ncbi.nlm.nih.gov/pmc/articles/PMC4292173. DOI:10.3389/f med.2014.00054.
[26] Ilivitzki A, Radan L, Ben-Arush M, et al. Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT[J]. Pediatr Radiol, 2013, 43(1):86-92. DOI:10.1007/s00247-012-2517-9.
[27] Depas G, De Barsy C, Jerusalem G, et al. 18F-FDG PET in children with lymphomas[J]. Eur J Nucl Med Mol Imaging, 2005, 32(1):31-38. DOI:10.1007/s00259-004-1604-z.
[28] Furth C, Steffen IG, Erdrich AS, et al. Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients[J]. EJNMMI Res, 2013, 3(1):71. DOI:10.1186/2191-219X-3-71.
[29] Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma[J]. Blood, 2006, 107(1):52-59. DOI:10.1182/blood -2005-06-2252.
[30] Bhojwani D, McCarville MB, Choi JK, et al. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma[J]. Br J Haematol, 2015, 168(6):845-853. DOI:10.1111/b jh.13219.
[31] Furth C, Steffen IG, Amthauer H, e t al. Early and late therapy response assessment with[18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin’s lymphoma:analysis of a prospective multicenter trial[J]. J Clin Oncol, 2009, 27(26):4385-4391. DOI:10.1200/JCO.2008.19.7814.
[32] Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate[J]. J Pediatr Hematol Oncol, 2006, 28(11):711-714. DOI:10.1097/01.mph.0000243648.66734.eb.
[33] Meany HJ, Gidvani VK, Minniti CP. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma[J]. Pediatr Blood Cancer, 2007, 48(4):399-402. DOI:10.1002/pbc.20797.
[34] Longo DL. Treatment of advanced Hodgkin lymphoma:the more things change, the more they stay the same[J]. J Clin Oncol, 2013, 31(6):660-662. DOI:10.1200/JCO.2012.44.7235.
[35] Nievelstein RA, van Ufford HM Q, Kwee TC, et al. Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma[J]. Eur Radiol, 2012, 22(9):1946-1954. DOI:10.1007/s00330-012-2447-9.
[36] Voss SD, Chen L, Constine LS, et al. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin’s lymphoma:a report from the Children’s Oncology Group[J]. J Clin Oncol, 2012, 30(21):2635-2640. DOI:10.1200/JCO.2011.40.7841.
[37] Rathore N, Eissa HM, Margolin JF, et al. Pediatric Hodgkin lymphoma:are we over-scanning our patients?[J]. Pediatr Hematol Oncol, 2012, 29(5):415-423. DOI:10.3109/08880018.2012.684198.
[38] Eissa HM, Allen CE, Kamdar K, et al. Pediatric Burkitt’s lymphoma and diffuse B-cell lymphoma:are surveillance scans required?[J]. Pediatr Hematol Oncol, 2014, 31(3):253-257. DOI:10.3109/08880018.2013.834400.
[39] Voss SD. Surveillance imaging in pediatric Hodgkin Lymphoma[J]. Curr Hematol Malig Rep, 2013, 8(3):218-225. DOI:10.1007/s11899-013-0168-z.
[40] Nievelstein RA, van Ufford HM Q, Kwee TC, et al. Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma[J]. Eur Radiol, 2012, 22(9):1946-1954. DOI:10.1007/s00330-012-2447-9.
[41] Abdel RH, Sedky M, Hamoda A, et al. Role of FDG-PET scan in the management of pediatric mature B cell non-Hodgkin’s lymphoma. CCHE experience[J]. J Egypt Natl Canc Inst, 2016, 28(2):95-99. DOI:10.1016/j.jnci.2016.03.003.
[42] Juweid ME. FDG-PET/CT in lymphoma[J]. Methods Mol Biol, 2011, 727:1-19. DOI:10.1007/978-1-61779-062-1_1.
[43] Schäffer JF, Gatidis S, Schmidt H, et al. Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology:initial results[J]. Radiology, 2014, 273(1):220-231. DOI:10.1148/radiol.14131732.
[44] Daldrup-Link H. How PET/MR Can Add Value For Children With Cancer[J]. Curr Radiol Rep, 2017, 5(3):15. DOI:10.1007/s40134-017-0207-y.

相似文献/References:

[1]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
　Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[2]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
　You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[3]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
　Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[4]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
　Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[5]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
　Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[6]曹登敏,林美福,陈文新,等.继发性骨淋巴瘤的18F-FDG PET/CT影像学表现[J].国际放射医学核医学杂志,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
　Cao Dengmin,Lin Meifu,Chen Wenxin,et al.Analysis on 18F-FDG PET/CT imaging characteristics in secondary bone lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
[7]李生栩,唐明灯,林端瑜,等.18F-FDG PET/CT在胸段食管鳞癌淋巴结转移中的诊断价值[J].国际放射医学核医学杂志,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
　Li Shengxu,Tang Mingdeng,Lin Duanyu,et al.Value of 18F-FDG PET/CT in detecting metastatic lymph nodes of thoracic esophageal squamous cell carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
[8]张莹莹,王振光,武凤玉,等.特发性肺间质纤维化HRCT病变区与非病变区18F-FDG PET/CT表现分析[J].国际放射医学核医学杂志,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
　Zhang Yingying,Wang Zhenguang,Wu Fengyu,et al.18F-FDG PET/CT imaging analysis of regions with abnormal and normal pulmonary parenchyma on high resolution CT in idiopathic pulmonary fibrosis patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
[9]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
　Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[10]郝新忠,武志芳,武萍,等.SAPHO综合征18F-FDG PET/CT显像和临床分析[J].国际放射医学核医学杂志,2015,39(6):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]
　Hao Xinzhong,Wu Zhifang,Wu Ping,et al.18F-FDG PET/CT imaging and clinical features of SAPHO syndrome[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]
[11]陈挺,张宏,田梅.18F-FDG PET/CT代谢半定量参数在非小细胞肺癌预后评估中的价值[J].国际放射医学核医学杂志,2018,(3):269.[doi:10.3760/cma.j.issn.1673-4114.2018.03.014]
　Chen Ting,Zhang Hong,Tian Mei.Prognostic evaluation of patients with non-small cell lung cancer by using semi-quantitative metabolic parameters of 18F-FDG PET/CT[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):269.[doi:10.3760/cma.j.issn.1673-4114.2018.03.014]
[12]杜芬,胡珊,梁梦,等.18F-FDG PET/CT显像在甲状腺偶发瘤良恶性诊断中的研究进展[J].国际放射医学核医学杂志,2018,(3):274.[doi:10.3760/cma.j.issn.1673-4114.2018.03.015]
　Du Fen,Hu Shan,Liang Meng,et al.Development in the diagnosis of benign and malignant thyroid incidentalomas by 18F-FDG PET/CT imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):274.[doi:10.3760/cma.j.issn.1673-4114.2018.03.015]
[13]段晓蓓,陈相猛,黄斌豪,等.18F-FDG PET/CT显像在肾上腺转移瘤中的诊断价值和预测分析[J].国际放射医学核医学杂志,2018,(4):307.[doi:10.3760/cma.j.issn.1673-4114.2018.04.003]
　Duan Xiaobei,Chen Xiangmeng,Huang Binhao,et al.18F-FDG PET/CT diagnostic value and predictive analysis in adrenal metastasis lesions[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):307.[doi:10.3760/cma.j.issn.1673-4114.2018.04.003]
[14]麻广宇,刘家金,徐白萱,等.11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究[J].国际放射医学核医学杂志,2018,(4):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
　Ma Guangyu,Liu Jiajin,Xu Baixuan,et al.Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
[15]谭延林,董楚宁,王云华.18F-FDG PET/CT在肺癌疗效评估中的价值[J].国际放射医学核医学杂志,2018,(4):357.[doi:10.3760/cma.j.issn.1673-4114.2018.04.013]
　Tan Yanlin,Dong Chuning,Wang Yunhua.The value of 18F-FDG PET/CT on evaluating therapeutic effect in the treatment of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):357.[doi:10.3760/cma.j.issn.1673-4114.2018.04.013]
[16]柳卫,李天女,范磊,等.肺大细胞神经内分泌癌的18F-FDG PET/CT表现[J].国际放射医学核医学杂志,2018,(6):486.[doi:10.3760/cma.j.issn.1673-4114.2018.06.002]
　Liu Wei,Li Tiannyu,Fan Lei,et al.18F-FDG PET/CT manifestations of pulmonary large cell neuroendocrine carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):486.[doi:10.3760/cma.j.issn.1673-4114.2018.06.002]
[17]徐鑫,邓胜明,李继会,等.18F-FDG PET/CT在胃癌分期、复发检测及预后评估中的应用价值[J].国际放射医学核医学杂志,2018,(6):541.[doi:10.3760/cma.j.issn.1673-4114.2018.06.012]
　Xu Xin,Deng Shengming,Li Jihui,et al.Progress in research on the use of 18F-FDG PET/CT in the staging, recurrence detection, and prognosis evaluation of patients with gastric carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):541.[doi:10.3760/cma.j.issn.1673-4114.2018.06.012]

备注/Memo

备注/Memo:
收稿日期:2018-01-08。
通讯作者:吴翼伟,Email:wuyiwei3988@gmail.com
更新日期/Last Update: 2018-12-31